Latest reporting
Latest in Drug Discovery & Research
DeepMind Alumni's AI Biotech Lands Third Major Cancer Data Deal in Five Months
Bioptimus secures access to 1,750+ UK colorectal cancer patient profiles as it races to build a 100,000-specimen foundation model for precision oncology.
Claude AI Outperforms Human Scientists in Protein Design Competition, Validating 354 Functional Binders
Anthropic's general-purpose AI achieved hit rates up to 35% in lab-validated protein engineering tests—more than double the industry standard—while analyzing complex chemistry data in minutes instead of days.
The Patent Paradox Threatening Billions in AI-Discovered Drugs
As artificial intelligence designs novel therapeutics with minimal human input, U.S. patent law's human-inventor requirement is creating legal uncertainty that could invalidate exclusivity rights for an entire generation of AI-developed medicines.
AI Agent Designs 354 Protein Binders in 48 Hours, Doubling Industry Success Rates
Anthropic's autonomous models orchestrated existing computational tools to generate high-affinity binders across oncology targets, achieving hit rates up to 35% compared to a 10-15% field norm.
The Validation Gap: Why AI-Designed Antibodies Just Hit Their First Real-World Reality Check
A landmark Nature Biotechnology benchmark reveals wildly inconsistent performance across 29 organizations' AI platforms, exposing the fragile evidence base beneath computational drug discovery's regulatory future.
Digital Pathology Alliance Aims to Streamline AI-Powered Cancer Diagnostic Development
Imagene AI's integration with Proscia's platform creates end-to-end pathway for pharmaceutical companies to develop companion diagnostics from discovery through clinical deployment.
AI Slashes Cancer Drug Development Costs by 90%, Biotech Claims—But Can the Model Scale?
Lantern Pharma reports its artificial intelligence platform reduces early-stage oncology development costs to $2-3 million per program, a fraction of traditional industry spending, while spinning out the technology as a commercial software business.
Drug Discovery's New Speed Limit: How AI Slashed a Decade-Long Process to 18 Months
Insilico Medicine's breakthrough pulmonary fibrosis candidate reached Phase 2 trials in record time, forcing clinical operators to rethink procurement, trial partnerships, and patient engagement strategies.
AI Monitoring Agent Delivers 82x ROI and $21 Million Gains in Cancer Drug Trials, Tufts Analysis Finds
First evidence-based financial modeling of agentic AI in drug development shows Medable's clinical monitoring system accelerates oncology programs by 10 weeks while slashing on-site monitoring costs.
AI Platform Delivers Eye Drop Candidate That Triples Efficacy Against Leading Cause of Vision Loss
Insilico Medicine's generative chemistry AI produces ISM9077 in half the traditional timeline, targeting dry AMD and inflammatory eye diseases with superior preclinical performance.
The $8.9 Billion Question: Why AI Drug Discovery Still Has Nothing on Pharmacy Shelves
Three years of sliding approval timelines expose a critical gap between artificial intelligence's preclinical promise and the regulatory infrastructure needed to bring AI-discovered medicines to patients.
Scientists Use AI to Engineer Living Viruses From Scratch, Raising Biosecurity Alarms
Stanford and Arc Institute researchers deployed an AI model to create 16 functional bacteriophages never seen in nature, demonstrating breakthrough genomic design capabilities that experts warn could be weaponized.
The Manufacturing Gap Threatening AI Drug Discovery's Promise
As AI-designed therapeutics reach human trials, venture capital firms warn that experimental validation and production capacity—not computational power—now determine which digital molecules become real medicines.
From Black Box to Bedside: How AI Is Finally Solving Cancer Immunotherapy's Biggest Prediction Problem
New multimodal AI models are outperforming traditional biomarkers in predicting which patients will respond to immunotherapy, potentially ending the era of trial-and-error treatment selection.
AI Brain Mapping Reveals Why Alzheimer's Tau Proteins Spread Differently at Each Disease Stage
New multi-layer network model pinpoints how toxic proteins travel through distinct brain pathways as dementia progresses, opening doors to precision-timed therapies.
How One Cloud Platform Is Solving AI's Biggest Genomics Problem
DNAnexus positions itself as the critical infrastructure layer connecting massive genomic datasets with artificial intelligence-driven precision medicine applications.
Why Biotech's AI Revolution Is Finally Moving Beyond the Lab and Into the Clinic
Nine companies reveal how artificial intelligence is tackling drug development's 90% failure rate by predicting which therapies will actually work in patients, not just in petri dishes.
Clinical Trial AI Gets a Major Overhaul as Medidata Bets on Platform Integration Over Point Solutions
New embedded AI layer aims to solve biopharma's fragmented tooling problem as industry leaders admit 71% of current AI deployments fall short of expectations.
AI Scientists Are Now Running Their Own Labs: Stanford Unveils Autonomous Research Agents That Generate Hypotheses and Write Papers
Stanford Medicine researchers deploy AI agents that function as virtual lead investigators, conducting biomedical research from hypothesis generation through manuscript preparation with minimal human oversight.
Pharma's Computational Arms Race Heats Up as Bristol Myers Squibb Builds Supercomputing Drug Discovery Powerhouse
Bristol Myers Squibb partners with Nvidia to deploy what it claims will be the life sciences industry's most powerful AI infrastructure, signaling an escalating battle for computational supremacy in drug development.
Diagnostic Giant Labcorp Enters AI Drug Discovery Race With Decades of Patient Data as Secret Weapon
Laboratory testing leader leverages billions of clinical test results spanning years to challenge specialized AI drug discovery firms and reshape pharmaceutical research.
AI Pathology Giants Unite: How Eight Companies Plan to Reshape Drug Development from the Inside
South Korea's Lunit joins global consortium targeting the pharmaceutical value chain with AI-powered biomarker discovery and patient selection technologies.
Nobel Winner's 100-Person Lab Tackles AI Protein Design's Billion-Dollar Manufacturing Problem
David Baker's University of Washington team can now computationally design full antibodies from scratch, but translating digital proteins into stable drugs remains the industry's defining challenge.
OpenAI Loses Another AI Scientist to Booming Drug Discovery Gold Rush as Researcher Eyes $2 Billion Valuation
Miles Wang's departure to launch an AI-powered drug repurposing startup highlights the accelerating exodus of talent from general AI labs to specialized healthcare ventures.
AI Drug Discovery Firm Lands Second $177M Deal in 90 Days as Platform Monetization Accelerates
Insilico Medicine's rapid-fire partnerships with China Medical System signal a pivotal shift from AI platform development to commercial-stage drug discovery, with CNS target identified entirely by generative algorithms.
Big Tech's Billion-Dollar Blind Spot: Why AI Giants May Stumble in the Drug Development Race
Anthropic joins the pharma AI rush, but industry insiders warn that cracking molecular codes is the easy part—surviving clinical trials demands data these companies don't have.
Big Pharma Bets Big on AI: Takeda Partners with Insilico to Reinvent Drug Discovery Pipeline
Major pharmaceutical company taps generative AI platform to slash development timelines and identify novel drug candidates across multiple therapeutic areas.
RNA-Targeting Breakthrough: Ionis Scores Dual Wins with First-Ever FCS Therapy and $430M Licensing Deal
FDA approval of Tryngolza for ultra-rare pancreatitis disorder and major partnership for hereditary angioedema treatment signal growing confidence in antisense oligonucleotide technology.
Why the FDA Is Betting on Biology-Driven AI to Fix Drug Development's $2 Billion Failure Problem
Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.
Pharma Giant Bets Half a Billion on Chip-Based Antibody Platform That Could Revolutionize Drug Hunting
Merck commits up to $510 million in milestone payments to Protillion Biosciences for AI-powered antibody discovery using on-chip screening technology.